Targeting B Cell Receptor Signalling in Cancer: Preclinical and Clinical Advances

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2018 Jan 20

PMID 29348577

Citations 200

Authors

Jan A Burger

Adrian Wiestner

Affiliations

Soon will be listed here.

Abstract

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive immunity. BCR signalling also supports the survival and growth of malignant B cells in patients with B cell leukaemias or lymphomas. The mechanism of BCR pathway activation in these diseases includes continuous BCR stimulation by microbial antigens or autoantigens present in the tissue microenvironment, activating mutations within the BCR complex or downstream signalling components and ligand-independent tonic BCR signalling. The most established agents targeting BCR signalling are Bruton tyrosine kinase (BTK) inhibitors and PI3K isoform-specific inhibitors, and their introduction into the clinic is rapidly changing how B cell malignancies are treated. B cells and BCR-related kinases, such as BTK, also play a role in the microenvironment of solid tumours, such as squamous cell carcinoma and pancreatic cancer, and therefore targeting B cells or BCR-related kinases may have anticancer activity beyond B cell malignancies.

Citing Articles

Generation and Reactivity Profiling of Functional Human Recombinant Monoclonal Antibodies.

Iatrou A, Fitopoulou M, Agathangelidis A Methods Mol Biol. 2025; 2909:269-297.

PMID: 40029528 DOI: 10.1007/978-1-0716-4442-3_18.

Immune dysregulation in COVID-19 induced ARDS in kidney transplant recipients revealed by single-cell RNA sequencing.

Pang J, Huang J, Yu J, Li B, Wei S, Cen W Sci Rep. 2025; 15(1):6895.

PMID: 40011702 PMC: 11865448. DOI: 10.1038/s41598-025-91439-5.

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.

Bai H, Zhou D, Liu J, He J, Min Z, Fan W Front Immunol. 2025; 16:1520470.

PMID: 39935483 PMC: 11810973. DOI: 10.3389/fimmu.2025.1520470.

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.

Xia Y, Huang Y, Liu Z, Song S, Wang Y, Luo J Front Immunol. 2025; 16:1548102.

PMID: 39925800 PMC: 11802514. DOI: 10.3389/fimmu.2025.1548102.

References

OBrien S, Lamanna N, Kipps T, Flinn I, Zelenetz A, Burger J . A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25):2686-94. PMC: 4732760. DOI: 10.1182/blood-2015-03-630947. View

Locatelli S, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A . The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016; 30(12):2402-2405. DOI: 10.1038/leu.2016.224. View

Satterthwaite A, Li Z, Witte O . Btk function in B cell development and response. Semin Immunol. 1998; 10(4):309-16. DOI: 10.1006/smim.1998.0123. View

Schmitz R, Young R, Ceribelli M, Jhavar S, Xiao W, Zhang M . Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418):116-20. PMC: 3609867. DOI: 10.1038/nature11378. View

Woyach J, Ruppert A, Guinn D, Lehman A, Blachly J, Lozanski A . BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017; 35(13):1437-1443. PMC: 5455463. DOI: 10.1200/JCO.2016.70.2282. View

Pylayeva-Gupta Y, Das S, Handler J, Hajdu C, Coffre M, Koralov S . IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov. 2015; 6(3):247-55. PMC: 5709038. DOI: 10.1158/2159-8290.CD-15-0843. View

Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang B . Ibrutinib inhibits pre-BCR B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2016; 129(9):1155-1165. PMC: 5374732. DOI: 10.1182/blood-2016-06-722900. View

Herndon T, Chen S, Saba N, Valdez J, Emson C, Gatmaitan M . Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017; 31(6):1340-1347. PMC: 5462849. DOI: 10.1038/leu.2017.11. View

Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D . CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009; 69(9):4001-9. DOI: 10.1158/0008-5472.CAN-08-4173. View

10.

Chu C, Catera R, Zhang L, Didier S, Agagnina B, Damle R . Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010; 115(19):3907-15. PMC: 2869555. DOI: 10.1182/blood-2009-09-244251. View

11.

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

12.

Sehn L . Introduction to a review series: the paradox of indolent B-cell lymphoma. Blood. 2016; 127(17):2045-6. DOI: 10.1182/blood-2016-03-692442. View

13.

Turner M, Mee P, Costello P, Williams O, Price A, Duddy L . Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995; 378(6554):298-302. DOI: 10.1038/378298a0. View

14.

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

15.

de Gorter D, Beuling E, Kersseboom R, Middendorp S, van Gils J, Hendriks R . Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007; 26(1):93-104. DOI: 10.1016/j.immuni.2006.11.012. View

16.

Allen C, Okada T, Cyster J . Germinal-center organization and cellular dynamics. Immunity. 2007; 27(2):190-202. PMC: 2242846. DOI: 10.1016/j.immuni.2007.07.009. View

17.

Sebastian E, Alcoceba M, Balanzategui A, Marin L, Montes-Moreno S, Flores T . Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am J Pathol. 2012; 181(5):1879-88. DOI: 10.1016/j.ajpath.2012.07.028. View

18.

Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P . FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2015; 127(6):739-48. DOI: 10.1182/blood-2015-06-654111. View

19.

Allen C, Ansel K, Low C, Lesley R, Tamamura H, Fujii N . Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004; 5(9):943-52. DOI: 10.1038/ni1100. View

20.

Shaffer 3rd A, Young R, Staudt L . Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012; 30:565-610. PMC: 7478144. DOI: 10.1146/annurev-immunol-020711-075027. View